GSK's Votrient launched in UK for kidney cancer
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has launched its anti-angiogenic, multi-targeted tyrosine kinase inhibitor Votrient (pazopanib) in the UK for the first-line treatment of advanced renal cell carcinoma (RCC), and for patients who have previously received cytokine therapy.